Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?
Locatelli
Francesco
F
Aljama
Pedro
P
Barany
Peter
P
Canaud
Bernard
B
Carrera
Fernando
F
Eckardt
Kai-Uwe
KU
Macdougall
Iain C
IC
Macleod
Alison
A
Hörl
Walter H
WH
Wiecek
Andrzej
A
Cameron
Stewart
S
D001323:Autoantibodies / Q000187:drug effects* / Q000378:metabolism; D004920:Erythropoiesis / Q000187:drug effects / Q000276:immunology*; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D011379:Prognosis; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000517:prevention & control; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods; D018570:Risk Assessment; D012720:Severity of Illness Index
D001323:Autoantibodies; D011994:Recombinant Proteins; D004921:Erythropoietin